2021
DOI: 10.1021/acs.inorgchem.1c03227
|View full text |Cite
|
Sign up to set email alerts
|

Loading and Sustained Release of Pralidoxime Chloride from Swellable MIL-88B(Fe) and Its Therapeutic Performance on Mice Poisoned by Neurotoxic Agents

Abstract: Maintaining a long-term continuous and stable reactivator blood concentration to treat organophosphorus nerve agent poisoning using acetylcholinesterase (AChE) reactivator pralidoxime chloride (2-PAM) is very important yet difficult. Because the flexible framework of MIL-88B(Fe) nanoparticles (NPs) can swell in polar solvents, pralidoxime chloride (2-PAM) was loaded in MIL-88B(Fe) NPs (size: ca. 500 nm) by stirring and incubation in deionized water to obtain 2-PAM@MIL-88B(Fe), which had a maximum drug loading … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3

Citation Types

1
8
0

Year Published

2022
2022
2025
2025

Publication Types

Select...
8

Relationship

2
6

Authors

Journals

citations
Cited by 10 publications
(9 citation statements)
references
References 42 publications
1
8
0
Order By: Relevance
“…The temperature range of decomposition of 2-PAM is basically comparable with the data reported in the literature. 37,38 In the fourth and final stage (>400 °C), the bio-MOF-1 framework decomposed, which is consistent with previous reports. 19 From the TGA analysis result together with the elemental analysis result, it was determined that the loaded 2-PAM accounted for 21.7 wt % of the 2-PAM@bio-MOF-1.…”
Section: ■ Introductionsupporting
confidence: 91%
“…The temperature range of decomposition of 2-PAM is basically comparable with the data reported in the literature. 37,38 In the fourth and final stage (>400 °C), the bio-MOF-1 framework decomposed, which is consistent with previous reports. 19 From the TGA analysis result together with the elemental analysis result, it was determined that the loaded 2-PAM accounted for 21.7 wt % of the 2-PAM@bio-MOF-1.…”
Section: ■ Introductionsupporting
confidence: 91%
“…To achieve sustained and stable blood drug concentrations and to overcome the blood−brain barrier, drug-loading materials are considered the best solution. Thus, liposomes, 24−27 PLGA, 28 and metal organic frameworks (MOFs) 29,30 have been loaded with 2-PAM, and only a few in vivo tests have been reported. [24][25][26][27]29 Although these works have shown promising results, the problem has not yet been solved, and the development of nanoformulations of 2-PAM and their application for protection of the central nervous system is still in its infancy.…”
Section: Introductionmentioning
confidence: 99%
“…To achieve sustained and stable blood drug concentrations and to overcome the blood–brain barrier, drug-loading materials are considered the best solution. Thus, liposomes, PLGA, and metal organic frameworks (MOFs) , have been loaded with 2-PAM, and only a few in vivo tests have been reported. , Although these works have shown promising results, the problem has not yet been solved, and the development of nanoformulations of 2-PAM and their application for protection of the central nervous system is still in its infancy. Among the various types of drug carriers reported, MOFs are considered to be a very promising class of drug carriers with advantages, such as easy surface functionalization, high drug loading capacity, controllable drug release in biological environments, controllable synthetic particle size, and adjustable pore size .…”
Section: Introductionmentioning
confidence: 99%
“…Oximes exert a nucleophilic attack on the P atom of the enzyme–OP adduct, resulting in removal of the phosphoryl moiety from the enzyme active site and the eventual AChE reactivation . However, while low oxime concentrations lead to inefficient reactivation rates, large amounts of reactivator have been shown to cause inhibition of the enzyme. , Thus, oxime dosage is a key parameter during OP-poisoning detoxification. In this sense, the current treatment entails the intravenous administration of a small reactivator dose for multiple times.…”
mentioning
confidence: 99%
“…In this sense, the current treatment entails the intravenous administration of a small reactivator dose for multiple times. However, this method generates significant fluctuations in the oxime concentration in the blood, resulting in a poor therapeutic performance . Therefore, novel systems ensuring a controlled and sustained oxime concentration in the body are highly targeted .…”
mentioning
confidence: 99%